Skip to main content
SpringerLink
Log in

Authors’ Reply to Gough: “Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes”

  • Letter to the Editor
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gough S. Comment on: “Achieving glycaemic control with concentrated insulin in patients with type 2 diabetes”. Drugs. 2019. https://doi.org/10.1007/s40265-019-01092-2.

    Article  PubMed  Google Scholar 

  2. Chatterjee S, Khunti K, Davies MJ. Achieving glycaemic control with concentrated insulin in patients with type 2 diabetes. Drugs. 2019;79(2):173–86.

    Article  CAS  PubMed  Google Scholar 

  3. Jonassen I, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diab Obes Metab. 2017;19(1):3–12.

    Article  CAS  Google Scholar 

  5. Kadowaki T, et al. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: a randomized, 26-week, treat-to-target trial. J Diabetes Investig. 2016;7(5):711–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Riddle MC, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Novo Nordisk. Tresiba prescribing information. https://www.novo-pi.com/tresiba.pdf. Accessed 4 Mar 2019.

  8. Tresiba: EPAR—product information. https://www.ema.europa.eu/en/documents/product-information/tresiba-epar-product-information_en.pdf. Accessed 4 Mar 2019.

Download references

Author information

Authors and Affiliations

  1. University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK

    Sudesna Chatterjee

  2. Abbott Diabetes Care, Abbott Laboratories, Maidenhead, UK

    Sudesna Chatterjee

  3. Diabetes Research Centre, University of Leicester, Leicester, UK

    Kamlesh Khunti & Melanie Davies

Authors
  1. Sudesna Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamlesh Khunti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melanie Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sudesna Chatterjee.

Additional information

This reply refers to the letter available at doi: https://doi.org/10.1007/s40265-019-01092-2.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chatterjee, S., Khunti, K. & Davies, M. Authors’ Reply to Gough: “Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes”. Drugs 79, 683–684 (2019). https://doi.org/10.1007/s40265-019-01093-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01093-1

Search

Navigation